Severity of COVID-19 in patients with lung cancer: evidence and challenges.

Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have consistently been reported to suffer from an increased risk of death compared with other cancers. This is possibly due to the combination of specific pathophysiological aspects, including underlying pulmonary compromise due to smoking history and the increased specific pressures on respiratory healt... Mehr ...

Verfasser: Passaro, A.
Bestvina, C.
Velez Velez, M.
Garassino, M.C.
Garon, E.
Peters, S.
Dokumenttyp: review
Erscheinungsdatum: 2021
Schlagwörter: Antineoplastic Agents/therapeutic use / COVID-19/complications / COVID-19/mortality / COVID-19/physiopathology / Carcinoma / Non-Small-Cell Lung/complications / Non-Small-Cell Lung/therapy / China / Humans / Immune Checkpoint Inhibitors/therapeutic use / Italy / Lung Neoplasms/complications / Lung Neoplasms/therapy / Mortality / Netherlands / Pneumonectomy / Radiotherapy / Risk Factors / SARS-CoV-2 / Severity of Illness Index / Small Cell Lung Carcinoma/complications / Small Cell Lung Carcinoma/therapy / United Kingdom / United States / COVID-19 / lung neoplasms
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29197482
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://serval.unil.ch/notice/serval:BIB_65ACCD8023E1

Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have consistently been reported to suffer from an increased risk of death compared with other cancers. This is possibly due to the combination of specific pathophysiological aspects, including underlying pulmonary compromise due to smoking history and the increased specific pressures on respiratory healthcare services caused by the related pandemic. Rationally and safely treating patients with lung cancer during the pandemic has become a continuous challenge over the last year. Deciding whether to offer, modify, postpone or even cancel treatments for this particular patient's population has become the crucial recurrent dilemma for lung cancer professionals. Chemotherapy, immunotherapy and targeted agents represent distinct risks factors in the context of COVID-19 that should be balanced with the short-term and long-term consequences of delaying cancer care. Despite the rapid and persistent trend of the pandemic, declared by WHO on March 11, 2020, and still ongoing at the time of writing (January 2021), various efforts were made by oncologists worldwide to understand the impact of COVID-19 on patients with cancer. Adapted recommendations of our evidence-based practice guidelines have been developed for all stakeholders. Different small and large-scale registries, such as the COVID-19 and Cancer Consortium (CCC19) and Thoracic Cancers International COVID-19 Collaboration quickly collected data, supporting cancer care decisions under the challenging circumstance created by the COVID-19 pandemic. Several recommendations were developed as guidance for prioritizing the various aspects of lung cancer care in order to mitigate the adverse effects of the COVID-19 healthcare crisis, potentially reducing the morbidity and mortality ...